Synthesized Nanostructured Dendrimer’s Proposal of a Practical Strategy to Improve the Solubility of Domperidone

An antiemetic drug called domperidone (DMP) is used to treat dyspepsia, indigestion, epigastric pain, nausea and vomiting in both adults and children. DMP is class II medication, which indicates that it has a high permeability and a low solubility in water. One major obstacle to the successful development of effective dosage forms for domperidone is its poor solubility in water. Dendrimers have shown to be useful as solubilizers in recent decades. Because of these unique properties, dendrimers are a useful tool for drug solubilization. These characteristics include good drug encapsulation, high water solubility, excellent host-guest chemistry, versatile geometry, and customizable surface design. The current study showed that synthesized dendritic macromolecules outperformed commercially available PAMAM dendrimer in novel nanostructure Dendrimer's cytotoxicity and hemolysis tests were performed on lung cancer cell lines, A-549. Using a phase solubility method, reported nanostructured dendrimers are used to increase the solubility of domperidone. The impact of dendrimer concentration and generation on domperidone solubility was investigated. The outcomes of the experiment demonstrated that domperidone's solubility was roughly correlated with dendrimer generation and concentration. Infrared spectroscopy is used to confirm the drug containing dendrimer. The current work indicates that the TG3.0 dendrimer exhibits significant promise for improving domperidone solubility. For increasing domperidone solubility, dendrimer worked better than beta-cyclodextrins. This research demonstrates that the hydroxyl-terminated nanostructured dendrimer system may serve as a promising delivery system for hydrophobic drugs.